Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612322 | 0.84 | GAA (0.49) | GAAMEN1KMT2AMAPTNPC1 | |
| SCHEMBL28294553 | 0.80 | MEN1 (0.56) | GAAMEN1KMT2AMAPTNPC1 | |
| SCHEMBL4498261 | 0.80 | GAA (0.51) | GAAMEN1KMT2AMAPTNPC1 | |
| SCHEMBL9386790 | 0.80 | MEN1 (0.55) | GAAMEN1KMT2AMAPTNPC1 | |
| Ammonia Solution, Strong SCHEMBL28128418 | 0.78 | MEN1 (0.54) | GAAMEN1KMT2AMAPTNPC1 | |
| SCHEMBL31144660 | 0.76 | CA1 (0.53) | GAAMEN1KMT2AMAPTNPC1 | |
| SCHEMBL4778707 | 0.76 | KMT2A (0.67) | GAAMEN1KMT2AMAPTNPC1 | |
| SCHEMBL9320810 | 0.76 | MEN1 (0.54) | GAAMEN1KMT2AMAPTNPC1 | |
| SCHEMBL6223043 | 0.75 | LDHA (0.43) | MEN1KMT2AMAPTRAB9ALMNA | |
| SCHEMBL11282600 | 0.74 | MEN1 (0.50) | GAAMEN1KMT2AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423388-B1 | 2-ARYLAMINO-PYRIMIDINES FOR THE TREATMENT OF GSK3-RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| CN-100415744-C | 2-arylamino-pyrimidines for the treatment of GSK3-related disorders | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | CN | disclosed |
| US-7176212-B2 | 2,4-diamino pyrimidine compounds having anti-cell proliferative activity | ASTRAZENECA AB (SE) | 2007-02-13 | — | — | US | disclosed |
| EP-1107957-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| CN-1823064-A | 2-arylamino-pyrimidines for the treatment of GSK 3-related disorders | ASTRAZENECA AB (SE) | 2006-08-23 | — | — | CN | disclosed |
| EP-1107958-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-16 | — | — | EP | disclosed |
| US-7078410-B2 | 2-arylamino-pyrimidines for the treatment of GSK3-related disorders | ASTRAZENECA AB (SE) | 2006-07-18 | — | — | US | disclosed |
| US-20050090493-A1 | 2,4-Diamino pyrimidine compounds having anti-cell proliferative activity | ASTRAZENECA AB | 2005-04-28 | — | — | US | disclosed |
| US-6855719-B1 | Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives | ASTRAZENECA AB (SE) | 2005-02-15 | — | — | US | disclosed |
| CN-1174981-C | Imidazo [1, 2-A ] pyridine and pyrazolo [2, 3-A ] pyridine derivatives | — | 2004-11-10 | — | — | CN | disclosed |
| US-20040106574-A1 | 2-Arylamino-pyrimidines for the treatment of gsk3-related disorders | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | US | disclosed |
| US-6670368-B1 | Anti-cell-proliferation (such as anti-cancer); inhibitors ofcell cycle kinases, particularly CDK2, CDK4, and CDK6; 4-(4-(2- hydroxy-3- (N,N-dimethylamino)propoxy)anilino)-2-(2,5-dimethylphenoxy) pyrimidine; | ASTRAZENECA AB (SE) | 2003-12-30 | — | — | US | disclosed |
| US-6632820-B1 | Anticancer agents | ASTRAZENECA AB (SE) | 2003-10-14 | — | — | US | disclosed |
| EP-1214318-B1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-08 | — | — | EP | disclosed |
| CN-1370163-A | Imidazo [1,2-A] pyridine and pyrazolo [2,3-a] pyridine derivatives | ASTRAZENECA AB (SE) | 2002-09-18 | — | — | CN | disclosed |
| EP-1107958-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-06-20 | — | — | EP | disclosed |
| EP-1107957-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012486-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012485-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090493-A1 | 2,4-Diamino pyrimidine compounds having anti-cell proliferative activity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-3, H1-0 | GAA 2340/4885MEN1 1601/4885KMT2A 1345/4885 |
| US-20040106574-A1 | 2-Arylamino-pyrimidines for the treatment of gsk3-related disorders | GSK3A, GSK3B, CKS2 | GAA 1316/4885MEN1 3655/4885KMT2A 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.